Angelini Pharma has announced that it will acquire Catalyst Pharmaceuticals in a deal worth around $4.1bn (3.5bn euros).
Angelini Pharma is an international pharmaceutical company and part of the Angelini Industries Group. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercialising novel medicines for patients living with rare and difficult-to-treat diseases.
The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the third quarter of 2026.
Following completion of the acquisition, Angelini Pharma intends to integrate Catalyst’s portfolio and commercial infrastructure with its own expertise and products in Brain Health to develop a next-generation therapeutic platform in rare diseases.
Catalyst’s portfolio is expected to significantly strengthen Angelini Pharma’s strategic objectives, growing its presence in the US as part of a balanced strategy that aims to develop the North American market while continuing to strengthen its core business in Europe.
Angelini Pharma’s continued industrial presence in Italy will remain a strategic asset as a valuable production and scientific centre within the combined company’s global operations.
Sergio Marullo di Condojanni, CEO of Angelini Pharma, commented: “[We believe] the acquisition of Catalyst Pharmaceuticals…will establish Angelini Pharma as a relevant global player in neurological rare diseases.
“Patient care remains at the heart of our vision. We continue to look ahead with determination, backed by a clear strategy and the drive to keep growing on a global scale.”
Rich Daly, President and CEO of Catalyst, commented: “By combining our unique capabilities in rare diseases with Angelini’s proven global reach, we will create a stronger, scalable and robust rare disease platform to expand access to life-changing therapies worldwide.”